Meet Dr. Steve Rose
Steve is highly respected for his expertise and tireless commitment to finding treatments and cures for vision-robbing retinal diseases.
Archive for May, 2012
ARVO Update: News on Gene Therapy Clinical Trials for RP and Choroideremia
Dr. Robert MacLaren
I was very excited to learn here at ARVO that two early-stage gene therapy clinical trials – one for choroideremia taking place in the U.K., the other for autosomal recessive retinitis pigmentosa (arRP) caused by MERTK mutations underway in Saudi Arabia – are proceeding well thus far. It is important to keep in mind that safety is the primary focus in these Phase I studies.
Read more
ARVO Poster: Nanoparticle Treatment Slows Vision Loss in Mice
The Sunday morning poster session at ARVO included a Foundation-funded research effort from Oklahoma University (OU) in which Dr. Lily Wong and her colleagues used a nanoceria treatment to slow retinal degeneration in a mouse model of autosomal dominant retinitis pigmentosa (adRP).
Join Me (and 11,000 Other Eye Specialists) in Fort Lauderdale
I invite you to join me, this coming week, in sunny Fort Lauderdale, Florida – not for spring break, but for something even better. As is always the case this time of year, the Association for Research in Vision and Ophthalmology (ARVO) will host its international conference, providing thousands of eye professionals with the latest information on retinal research and technologies.
The FDA’s Indispensible Role (a guest blog from Dr. Patricia Zilliox)
To get a sight-saving treatment or therapy to the commercial market in the United States, you need three basic things: 1) scientists to discover and develop it; 2) money to support the research; and 3) Food and Drug Administration (FDA) marketing approval. While it may not seem obvious, the FDA ultimately drives everything — the researchers and the money. That’s because without FDA approval, you have no treatment, even if you have great research and adequate funding.